SCHEMBL30748931

SCHEMBL30748931

C[C@@H]1CN(c2ccc(N3C(=O)C(C)(C)c4c(Cl)nc(Cl)nc43)cc2F)C[C@H](C)O1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 1/20 0.41
PDE3A Q14432 1/20 0.41
KDM4E B2RXH2 1/20 0.38
HTT P42858 1/20 0.38
TNKS O95271 1/20 0.36
PARP1 P09874 1/20 0.36
PARP10 Q53GL7 1/20 0.36
TNKS2 Q9H2K2 1/20 0.36
PARP2 Q9UGN5 1/20 0.36
MAPK14 Q16539 2/20 0.36
MAPK13 O15264 1/20 0.36
MAPK12 P53778 1/20 0.36
MAPK11 Q15759 1/20 0.36
USP30 Q70CQ3 1/20 0.35
KMT2A Q03164 4/20 0.35
TDP1 Q9NUW8 1/20 0.35
ALDH1A1 P00352 2/20 0.32
GAA P10253 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
BTK Q06187 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30748801 0.86 ELANE (0.37) KDM4EMAPK14KMT2ATDP1ALDH1A1
SCHEMBL30748904 0.84 RAD51 (0.42) PDE3BPDE3AALDH1A1SMN1; SMN2F10
SCHEMBL30748921 0.84 PDE3B (0.34) PDE3BPDE3AKDM4EHTTTNKS
SCHEMBL30748805 0.80 KMT2A (0.39) MAPK14KMT2ATDP1SMN1; SMN2BTK
SCHEMBL31691210 0.79 MAPK14 (0.35) MAPK14KMT2ATDP1GAASMN1; SMN2
SCHEMBL30749005 0.76 PDE3B (0.34) PDE3BPDE3AKDM4EHTTTNKS
SCHEMBL30748990 0.74 MEN1 (0.31) KMT2AALDH1A1GAASMN1; SMN2TSHR
SCHEMBL30749007 0.69 ELANE (0.44) KMT2ATDP1ALDH1A1
SCHEMBL30749132 0.69 RAB9A (0.41) KDM4EHTTKMT2ATDP1ALDH1A1
SCHEMBL15583991 0.67 KDM4E (0.46) PDE3BPDE3AKDM4EHTTUSP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT PDE3B 1053/4885PDE3A 1074/4885KDM4E 2102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.